Avantax Planning Partners, Inc. Clovis Oncology, Inc. Transaction History

Avantax Planning Partners, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$11.63 - $32.67 $1,581 - $4,443	-136 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$29.37 - $49.48 $3,994 - $6,729	136 New	136 $4,000
Q2 2018 Aug 13, 2018	SELL	$42.06 - $62.4 $5,720 - $8,486	-136 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$50.12 - $67.72 $6,816 - $9,209	136 New	136 $7,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Avantax Planning Partners, Inc., based on Form 13F filings with the SEC.

Stay updated on Avantax Planning Partners, Inc. with notifications on news.